As­traZeneca spins out a bis­pe­cif­ic an­ti­body in­to a new can­cer biotech with part­ner AbPro

As­traZeneca’s big sub­sidiary Med­Im­mune and syn­thet­ic bi­ol­o­gy play­er AbPro are join­ing forces on a spin-out com­pa­ny which will un­der­take the de­vel­op­ment of a pre­clin­i­cal bis­pe­cif­ic an­ti­body that tar­gets two key path­ways in­volved in can­cer.

The deal builds on Med­Im­mune’s team­work on first cre­at­ing the bis­pe­cif­ic, which in­hibits both Ang2 and VEGF path­ways. AbPro will now em­ploy its syn­thet­ic bi­ol­o­gy plat­form to re­fine the ther­a­py and take it in­to the clin­ic with a spin­out com­pa­ny op­er­at­ing un­der its or­ga­ni­za­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER